A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)

PHASE2CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

November 23, 2020

Primary Completion Date

February 27, 2024

Study Completion Date

February 27, 2024

Conditions
Alzheimer DiseaseDementiaBrain DiseasesCentral Nervous System DiseasesCognitive Impairment
Interventions
OTHER

No Intervention

No intervention

DRUG

donanemab

Administered IV

Trial Locations (27)

19001

Abington Neurological Associates, Ltd., Abington

23294

National Clinical Research, Inc, Richmond

27405

Guilford Neurologic Research, PA, Greensboro

32127

Progressive Medical Research, Port Orange

32806

Synexus Clinical Research US, Inc., Orlando

32952

Merritt Island Medical Research, LLC, Merritt Island

33410

Advanced Research Consultants, Palm Beach Gardens

33613

Stedman Clinical Trials, Tampa

34205

Bradenton Research Center, Inc., Bradenton

34239

Intercoastal Medical Group - Hyde Park, Sarasota

43210

Ohio State University, Columbus

45459

Neurology Diagnostics, Inc., Dayton

46202

Indiana University, Indianapolis

46256

Josephson Wallack Munshower Neurology, PC, Indianapolis

63110

Washington University, St Louis

66205

The University of Kansas - Clinical Research Center, Fairway

66606

Cotton O'Neil Clinical Research Center - Central Office, Topeka

85006

Banner Alzheimer's Institute, Phoenix

89113

Las Vegas Medical Research, Las Vegas

92697

UC Irvine-Institute for Memory Impairments and Neurological Disorders (UCI MIND), Irvine

02459

Boston Center for Memory, Newton

08755

Advanced Memory Research Institute of New Jersey, Toms River

02903

Rhode Island Hospital, Providence

K1N 5C8

Bruyère Research Institute, Ottawa

M3B 2S7

Toronto Memory Program, Toronto

J8T 8J1

Clinique de la Mémoire de l'Outaouais, Gatineau

J1L 0H8

Diex Recherche Sherbrooke Inc., Sherbrooke

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04640077 - A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT) | Biotech Hunter | Biotech Hunter